TMSP(SH:600671)2024-10-29 09:51Financial Performance - The company's operating revenue for Q3 2024 reached ¥65,132,048.43, representing an increase of 85.28% compared to the same period last year[2]. - The net profit attributable to shareholders was ¥14,805,182.89, a significant recovery from a loss of ¥3,695,546.06 in the previous year[2]. - The basic earnings per share for the quarter was ¥0.12, compared to a loss of ¥0.0303 per share in the same period last year[2]. - The total operating revenue for the first three quarters of 2024 reached CNY 124,680,446.71, a significant increase of 45% compared to CNY 86,107,172.19 in the same period of 2023[21]. - The total revenue from operating activities for the first three quarters of 2024 was 122,128,993.23 CNY, an increase from 88,135,065.52 CNY in the same period of 2023, representing a growth of approximately 38.5%[24]. - The net profit for the third quarter of 2024 was -3,761,066.17 CNY, compared to -27,526,126.34 CNY in the same period last year, showing a significant reduction in losses[22]. - The total comprehensive income for the third quarter of 2024 was -3,761,066.17 CNY, compared to -27,526,126.34 CNY in the same quarter of 2023[23]. - The company reported a net loss of CNY 275,305,704.34 for the first three quarters of 2024, compared to a net loss of CNY 271,610,158.28 in the same period of 2023[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥366,351,298.79, reflecting a 5.79% increase from the end of the previous year[3]. - The total liabilities increased to CNY 309,840,918.42 as of September 30, 2024, compared to CNY 290,340,095.74 at the end of 2023, representing a rise of 7%[20]. - Cash and cash equivalents decreased to CNY 30,426,181.81 as of September 30, 2024, down from CNY 97,962,612.42 at the end of 2023, representing a decline of approximately 69%[18]. - Accounts receivable increased to CNY 64,035,560.53 as of September 30, 2024, compared to CNY 36,683,351.80 at the end of 2023, indicating a growth of 74%[18]. - Inventory rose to CNY 46,732,499.13 as of September 30, 2024, compared to CNY 42,946,392.19 at the end of 2023, marking an increase of 18%[19]. - Non-current assets totaled CNY 216,046,037.21 as of September 30, 2024, up from CNY 164,789,303.06 at the end of 2023, reflecting a growth of 31%[19]. - The company’s fixed assets increased to CNY 166,998,592.65 as of September 30, 2024, compared to CNY 139,780,421.89 at the end of 2023, indicating a growth of 20%[19]. Cash Flow - Net cash flow from operating activities was -34.88 million RMB, with cash received from sales increasing by 33.99 million RMB, while cash paid for purchases increased by 44.57 million RMB[9]. - Net cash flow from investment activities was -334.87 million RMB, primarily due to increased cash payments for fixed assets and acquisitions of subsidiaries[9]. - The net cash flow from operating activities for the first three quarters of 2024 was -38,957,059.21 CNY, worsening from -28,882,242.08 CNY year-over-year[25]. - The cash inflow from financing activities in the third quarter of 2024 was 198,464,100.32 CNY, compared to 258,308,673.78 CNY in the same period of 2023[25]. - The company reported an investment cash outflow of 18,929,718.65 CNY in the third quarter of 2024, compared to 4,270,494.81 CNY in the same period last year[25]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 6,036[10]. - Major shareholder Qingdao Huilong Huaze Investment Co., Ltd. holds 29.99% of the shares, totaling 36,519,460 shares[10]. - Shareholder Qingdao Yuanjia Medical Technology Co., Ltd. plans to increase its stake by investing between 10 million and 20 million RMB within six months, having already acquired 265,200 shares for 1.6992 million RMB[13]. Future Plans and Developments - The company plans to continue expanding its market presence and developing new products, as indicated by the increase in construction projects and investments[8]. - The company plans to apply for a 100 million RMB working capital loan from China Minsheng Bank, with a one-year credit term, guaranteed by the company and its indirect controlling shareholder[15]. - The company has applied for a comprehensive credit line of 10 million RMB, including a 5 million RMB working capital loan and low-risk business[15]. - The company plans to issue A-shares to specific investors, pending approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission[17]. Regulatory Approvals and Subsidies - The company received approval for the consistency evaluation of Amoxicillin and Clavulanate Potassium Tablets (0.625g) from the National Medical Products Administration in July 2024[14]. - The company received re-registration approvals for 28 drug varieties from the Zhejiang Drug Administration during the reporting period[14]. - The company recorded government subsidies of ¥137,182.35 during the period, contributing to its financial performance[4]. - The total non-recurring gains and losses amounted to ¥612,562.45 for the period, with a significant portion related to government subsidies[5]. Research and Development - Research and development expenses decreased by 75.89 million RMB due to the completion of the consistency evaluation for Amoxicillin and Clavulanate Potassium Tablets[9].